Skip Navigation

Correction for Strohm et al., Cardiovasc Res 56 (3) 492.
Cardiovascular Research 2002 55(3):602-618; doi:10.1016/S0008-6363(02)00453-4
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Erratum (v56,p492)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Strohm, C.
Right arrow Articles by Schaper, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strohm, C.
Right arrow Articles by Schaper, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Transcription inhibitor actinomycin-D abolishes the cardioprotective effect of ischemic reconditioning

Claudia Strohma,,1, Miroslav Barancíkb,,1, Marie-Luise von Bruehla, Monika Strniskovab, Claudia Ullmanna, René Zimmermannc and Wolfgang Schapera,*

aDepartment of Experimental Cardiology, Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany
bInstitute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
cKerckhoff-Clinic, Vascular Genomics, Bad Nauheim, Germany

w.schaper{at}kerckhoff.mpg.de

* Corresponding author. Tel.: +49-6032-705-402; fax: +49-6032-705-419

Objective: Our previous studies have suggested a role of mitogen-activated protein kinases (MAPKs) in cardioprotection in the porcine heart. To investigate, whether this could be due to modification of transcriptional events we studied the influence of actinomycin-D (act-D), a known RNA-synthesis inhibitor on (i) ischemic preconditioning, (ii) (IP)-mediated cardioprotection, (iii) transcription factors levels and MAPKs activation. Methods: The IP-design in our model included two cycles of 10' LAD occlusion (CO) and 10' reperfusion (RP), followed by 40' CO (index ischemia) and 60' RP. Act-D was infused intramyocardially (i.my.) or systemically (syst.) (0.05 or 0.12 mg/kg) during 15' before IP and during both RP cycles of the IP-protocol. The i.my. infusions occurred via four pairs of needles into the risk area (RA). Results: Systemic infusion of act-D (0.05 mg/kg) before index ischemia significantly increased the IS from 54.0±2.5 to 78.5±3.8%. IP significantly reduced the IS to 2.5±0.8%. Syst. of act-D completely abolished the IP-induced cardioprotection. At a dose of 0.12 mg/kg the IS was 88.6±1.7% of the risk area; at 0.05 mg/kg IS was 65.6±1.5%. Local infusion of act-D reduced the IP-induced cardioprotection in a concentration dependent manner. Syst. or i.my. infusion of DMSO in KHB did not influence the IP-induced cardioprotection. Western blot analysis with phospho-specific antibodies showed a significant increase in phosphorylation of cytosolic ERK1/2 and SAPK/JNKs at the end of IP procedure and act-D treatment inhibited IP-induced activation of these MAPKs. By Western blot analysis using phospho-specific antibodies against c-Jun, ATF-2, Elk-1 and c-Myc we found increased phosphorylation of all these transcription factors in the myocardial risk area at the end of IP protocol and both local and systemic infusion of act-D significantly (P<0.05) inhibited this increased phosphorylation. Unlike UO, act-D had no influence on the Akt-pathway but inhibited the increased expression of S100 protein induced by IP. Conclusions: We demonstrate in vivo that act-D, completely cancelled the IP-induced cardioprotection. The influence of act-D on cardioprotection, transcription factors, and activities of ERKs and JNKs indicates a possible transcriptional role of these MAPKs signal transduction pathways during ischemia and in IP.

KEYWORDS Gene expression; Infarction; Preconditioning; Protein kinases; Protein phosphorylation; Signal transduction


1 Both authors contributed equally to this study.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Physiol. Rev.Home page
E. Murphy and C. Steenbergen
Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury
Physiol Rev, April 1, 2008; 88(2): 581 - 609.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Heidbreder, A. Naumann, K. Tempel, P. Dominiak, and A. Dendorfer
Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways
Cardiovasc Res, April 1, 2008; 78(1): 108 - 115.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
R. da Silva, E. Lucchinetti, T. Pasch, M. C. Schaub, and M. Zaugg
Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium
Physiol Genomics, December 15, 2004; 20(1): 117 - 130.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
I. E. Konstantinov, S. Arab, R. K. Kharbanda, J. Li, M. M. H. Cheung, V. Cherepanov, G. P. Downey, P. P. Liu, E. Cukerman, J. G. Coles, et al.
The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans
Physiol Genomics, September 16, 2004; 19(1): 143 - 150.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Vaage and G. Valen
Preconditioning and cardiac surgery
Ann. Thorac. Surg., February 1, 2003; 75(2): S709 - 714.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. M Yellon and J. M Downey
Spotlight on preconditioning
Cardiovasc Res, August 15, 2002; 55(3): 425 - 428.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.